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Poster Session I 69Introduction: Autologous stem cell transplantation is accepted
therapy for most younger patients with multiple myeloma (MM)
following steroid-based induction therapy. Use of dose-intense sal-
vage chemotherapy, such as D-PACE, in steroid-refractory MM
may adversely affect stem cell harvesting. Bortezomib (Bor), an
agent with a novel mechanism of action against MM, may be syner-
gistic to alkylating agents, and does not affect stem cell yield in pre-
treated patients.We piloted the addition of Bor to high-dose cyclo-
phosphamide (Cy) during stem cell harvesting in a series of patients
refractory to D-PACE salvage therapy. Patients and Methods: 17
MM patients refractory to 3 or more cycles of steroid-based induc-
tion therapy received 2 cycles of D-PACE in prior to proceeding to
autologous stem cell harvesting. 7 patients achieved adequate cytor-
eduction and proceeded to high-dose Cy (3 g/m2) and G-CSF plus
SCF stimulation for mobilization. In 10 patients not achieving ad-
equate disease cytoreduction, Bor was added to the mobilization
regimen prior to high-dose Cy. Response assessment included
time to stem cell harvest, number of CD34 cells harvested, disease
response, and effect on hematologic parameters. Results: Toxic-
ities arising from D-PACE were similar in both groups. The com-
bination Bor/Cy mobilization regimen did not lead to increased
symptomatic toxicity. Grade 3/4 thrombocytopenia occurred in 6/
10 patients receiving combination therapy. No significant bleeding,
peripheral neuropathy, or skin rash occured. The average CD341
stem cell harvest in both groups was .5.0  106/kg., and favored
the combination group. Time to adequate stem cell harvest was sim-
ilar between the groups. The harvested product from the Bor/Cy
group consistently demonstrated \2% cells bearing plasma cell
markers by flow cytometry. 1 patient in each group failed to mobi-
lize sufficient stem cells for an adequate harvest. Bone marrow
plasma cell content following Bor/Cy harvesting decreased in all as-
sessed patients. Time to engraftment was similar in both groups.
Data on post-transplant disease control and survival will be pre-
sented. Presence of unfavorable cytogenetics or ISS stage at diagno-
sis did not appear to affect response to Bor/Cy therapy.
Conclusion: The addition of Bor to high-dose Cy during stem
cell mobilization does not increase toxicity or decrease stem cell
harvest yield or quality, and achieves adequate disease reduction
in patients refractory to salvage chemotherapy.187
FLUDARABIN AND CYCLOPHOSPHAMIDE BASED NON-MYELOABLATIVE
CONDITIONING REGIMENS IN THE PATIENTS ALLOGRAFTED FOR
RECURRENT/REFRACTORY MALIGNANT LYMPHOPROLIFERATIVE
DISORDERS
Raida, L.1, Vondrakova, J.1, Faber, E.1, Papajik, T.1, Indrak, K.1,
Langova, K.2. 1University Hospital, Olomouc, Czech Republic; 2Medical
School of Palacky University, Olomouc, Czech Republic.
Background: Non-myeloablative conditionings combined
fludarabin and cyclophosphamide (FLU-CY) with or without
antithymocyte globulin (ATG) and low-dose total body irradiation
(LD-TBI) may be used in the patients allografted for malignant
lymphomas. Significant immunosuppressionwithout severe toxicity
allows to engraft donor cells responsible for desirable graft versus
lymphoma (GvL) reaction. Patients and Methods: 20 patients
with the age median of 49 (range 27–58) years were allografted
for relapsed and/or refractory malignant lymphoproliferative dis-
eases: 5 B chronic lymphocytic leukemia (B-CLL), 4Hodgkin’s
lymphoma (HL), 8 B and 3 T non-Hodgkin’s lymphoma
(NHL). 9 patients (45%) were conditioned with FLU-CY. ATG
only was added to FLU-CY in 6 cases (30%), ATG and LD-TBI
in 5 ones (25%). 9 patients (45%) received the graft from sibling,
6 (30%)matched unrelated and 5 ones (25%)mismatched unrelated
donor. Peripheral blood and bone marrow were the source of stem
cells in 17 (85%) and 3 cases (15%), respectively. The median of
transfused CD341 cells was 5.03 (range 2.5–8.8) 106/kg of recip-
ient body weight. Graft versus host disease (GvHD) prophylaxis
with cyclosporine A (CSP-A) only was administered to 10 recipients
(50%). Mycophenolate mofetil (MMF) and methotrexate (MTX)
were added to CSP-A in 9 (45%) and 1 cases (5%), respectively.
The median of posttransplant follow-up was 1.6 (range 0.3–5.7)
years. Results: All recipients engrafted and non-hematologicaltoxicity did not exceed the grade I. 10 ones (50%) developed acute
GvHD. Chronic GvHD was observed in 10 of 18 assessable cases
(55.6%). All patients (100%) achieved complete remission (CR) of
lymphoma. 4 ones (20%) relapsed and 2 of them (10%) died of tu-
mor progression. 7 recipients (35%) died of posttransplant compli-
cations. Estimated 5-year event-free (EFS) and overall survival (OS)
were 27% and 29%, respectively. Conclusion: The results con-
firmed a possibility to cure recurrent/refractory lymphoma by
GvL reaction without the previous significant tumor burden reduc-
tion.Nevertheless, GvHDand associated complications still remain
the main cause of posttransplant morbidity and mortality.
Supported by the Ministry of Education of the Czech Republic
(MSM-6198959205).188
SINGLE INSTITUTION’S OUTCOMES FOR FIRST TRANSPLANT AS SAL-
VAGE THERAPY FOR HODGKIN’S LYMPHOMA
Shafer, J.A.1,3, Heslop, H.E.1,2,3, Carrum, G.1,2, Kamble, R.1,2,
Myers, G.D.1,3, Leung, K.S.1,3, Bollard, C.M.1,2,3, Krance, R.A.1,2,3
1Baylor College ofMedicine; 2Baylor College ofMedicine; 3Baylor College
of Medicine, Houston, TX.
Survival Rates for patients diagnosed with Hodgkin’s lymphoma
(HL) approaches 90% irrespective of stage at initial diagnosis. But
for patients with primary refractory or relapsed disease the out-
comes are less favorable. High dose chemotherapy with stem cell
rescue has been shown to be the preferred salvage approach, with
overall survival rates ranging from 30–65%, compared to conven-
tional chemotherapy. Risk factors for poor outcomes include early
relapse and primary refractory disease and it is suggested that these
groupsmay benefit from allogenic transplant.However, the outlook
for patients with chemo-resistant disease is poor and it is unclear if
these patients receive any benefit from stem cell transplant. Here we
evaluate outcomes of patients who have received stem cell trans-
plant at our institution for relapsed or refractory Hodgkin’s disease.
A retrospective review of 42 patients who received their initial trans-
plant for Hodgkin’s disease between October of 1997 and June of
2007 at the Center for Cell and Gene Therapy in Houston, Texas
was performed. Indications for transplant included refractory dis-
ease at primary diagnosis or relapsed disease. 30 patients received
high dose chemotherapy with autologous stem cell rescue and 12
patients received an allogeneic HSCT. Indications for allogeneic
HSCT included chemorefractory disease and/or bone marrow in-
volvement of HL. The median age of the patients was 23.5 (range
12–60 years). Median time of follow up was 3 years (range 3 months
to 9 years). 5 year overall survival (OS) was 66% and progression
free survival (PFS) was 56%. Of the 7 patients transplanted (2
auto and 5 allo) with chemotherapy resistant disease only one pa-
tient survives (\1 year follow-up). The remaining 6 died within 3
years of SCT primarily due to disease progression. When these
highest risk patients with chemotherapy resistant disease are ex-
cluded in the analysis the OS and PFS after SCT is 76% and 66%
respectively. Our data supports the dismal results of patients with
chemo resistant disease, whereas patients with chemo-sensitive dis-
ease have a good chance of cure with HSCT.189
NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
TO TREAT HIGH RISK HEAVILY PRETREATED MULTIPLE
Moreb, J.S., Wirk, B.M., Cogle, C., Jamieson, K.J., Hsu, J.,
Wingard, J.R. University of Florida, Gainesville, FL.
Allogeneic stem cell transplantation (SCT) can induce long term
remissions and some cures in multiple myeloma (MM). High treat-
ment related mortality (TRM) associated with such treatment mo-
dality has been the reason behind exploring non-myeloblative
conditioning regimens (NMA) in these patients. As part of a pro-
spective study evaluating NMA for hematologic malignancies in
our institution, 12 MM patients were enrolled between 2000–
2006. All patients were transplanted as either part of initial
70 Poster Session Iinduction/consolidation treatment (n5 3) or as a salvage therapy af-
ter failing multiple prior therapies including autologous SCT (n 5
9). Median number of prior therapy was 4 (range, 2–7). Condition-
ing regimen consisted of fludarabine (180 mg/kg), busulfan (8 mg/
kg), and anti thymocyte globulin. Graft-vs-host disease (GVHD)
prophylaxis consisted of tacrolimus alone.
Results:Median age was 54 years with 50%males. Four patients
had matched unrelated donor (MUD) SCT and 8 had matched sib-
ling SCT. Median CD341 cell dose was 7  106/Kg ideal body
weight. All patients engrafted (with 100% donor chimerism) except
for one patient who died on day 19 due to severe fludarabine neu-
rotoxicity. Three patients never achieved zero absolute granulocyte
count (AGC) and 4 patients did not require platelet transfusions.
Time to AGC . 500 was 18.5 days (n 5 10), and to platelet .
20,000/ul was 12 days (n 5 7). TRM was seen in 3/12 patients
(25%), while 7 patients died of disease progression. The incidence
of grade II-IV acute and extensive chronic GVHD was 45% for
both. Post SCT donor lymphocyte infusions (2–4 infusions) were
used in conjunction with salvage therapy to treat persistent or re-
lapsed MM in 3 patients, all died of progressive disease. Overall re-
sponse rate was 55% with 6 of 11 patients achieving partial
remission or better, and only two patients achieving complete re-
mission. Median progression free and overall survival was 10 and
21.5 months. Currently, 3 patients are alive 31–75 months since
transplant, two of them after MUD SCT, one in complete remis-
sion and the other two with stable residual disease. One patient
never had prior autologous SCT. All three patients have been
treated for mild to moderate extensive chronic GVHD, but no
MM therapy. In conclusion, our results indicate that NMA alloge-
neic SCT is an effective salvage therapy in 25% of patients with ad-
vanced MM, however relapse remains the main reason for failure.PEDIATRIC DISORDERS190
THE EFFECT OF OVERWEIGHT ANDOBESITY ON INTRAVENOUS (IV) BU-
SULFAN METABOLISM IN CHILDREN UNDERGOING REDUCED INTEN-
SITY CONDITIONING (RIC) FOR ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (AHSCT)
Browning, B., Thormann, K., Coyne, K., Kletzel, M. Children’s Memo-
rial Hospital, Chicago, IL.
Pediatric obesity is growing problem in the US. According to the
Centers for Disease Control and Prevention (CDC), 16% of chil-
dren between the ages of 6–19 are considered overweight or obese
with an additional 15% of the pediatric population considered at
risk for becoming overweight. The purpose of this study was to in-
vestigate the predicted versus actual AUC of IV busulfan in children
who are overweight or obese to determine if increased body weight
and adiposity affects the metabolism of this drug.
Retrospective data was collected on 52 pediatric HSCT patients
from 2000–2007 at Children’s Memorial Hospital who underwent
RIC with fludarabine 25 mg/m2/day  5 days and busulfan (single
daily dose) dose adjusted by a test dose  2 days 1/- ATG. Test
dose (TD) of 0.8 mg/kg was given over 2 hrs 5–10 days prior to
stem cell infusion and pharmacokinetic (PK) blood draws were
taken at 4 time points (end of infusion, 30 min., 2, 4 hours post in-
fusion). Regimen doses (RD) were calculated from the AUC and
clearance of the TD and were initiated 5–4 days prior to stem cell
infusion. PK data was collected at 5 time points for the RD (end
of the infusion, 30 min., 2, 5, 24 hours post infusion). All samples
were sent to Seattle Cancer Care Alliance Clinical Pharmacokinet-
ics Laboratory for analysis and calculation of AUC and clearance.
Retrospective data collected included demographics, diagnosis, ht,
wt, calculated BMI, concomitant meds, liver function tests
(LFT’s), TD and RD AUCmMol*min, clearance ml/min/kg and
the dose of BU mg/kg given. Subject were graphed on standard
CDC body mass index (BMI) growth charts then stratified into
BMI categories: \25th%tile, 25–75th%tile, 85–95th%tile and
.95th%tile.
37% of the subjects were overweight or obese. 61% of the sub-
jects reached the targeted AUC with the TD; 80% of the subjects
reached the targeted AUC with the RD. Modifications were madeto the RD in 42 pts. No statistical significance was found between
BMI and TD AUC (p 5 0.31) or RD AUC (p 5 0.96). There was
also no statistical correlation between obtaining targeted TD or
RD AUC and age, sex, LFT’s, concomitant medications, source
of stem cells, diagnosis or weight. It was observed that more TD
and RD AUC anomalies occurred in children who were overweight
or obese. See table. Based on this data, no changes should be made
in current dosing for children who are overweight or obese if the
RD is based on a TD, however, more research with a larger sample
size is warranted.
AUC Trends in each BMI Category
85–95th%tile .95th%tileBMI \25th%tile 25–75th%tile (overweight) (obese)Total Number of Children in
Each Category14 19 9 1027% 37% 17% 19%Test Dose and Regimen Dose
CombinedTotal # of TD or RD AUC’s
\800 and .1200 or\3200 or
.4800 (lower or higher than
predicted)5 9 4 736% 47% 44% 70%Total # of low TD or RD
AUC’s\800 or\3200 (lower
than predicted)5 5 1 136% 26% 11% 10%Total # of high TD and RD
AUC’s .1200 or .4800
(higher than predicted)0 4 3 60% 21% 33% 60%Test DoseTotal # of low TDAUC’s
\800 (lower than predicted)
2 4 0 114% 21% 0% 10%Total # of high TD AUC’s
.1200 (higher than predicted)0 2 3 30% 11% 33% 30%Regimen DoseTotal # of low RD ACU’s
\3200 (lower than predicted)
3 1 1 021% 5% 11% 0%Total # of high RD ACU’s
.4800 (higher than predicted)0 2 0 30% 11% 0% 30%191
ATYPICAL TERATOID/RHABDOID TUMORS: IMPROVED OUTCOME WITH
HIGH-DOSE CHEMOTHERAPY
Schechter, T., Gassas, A., Bartels, U., Doyle, J., Bouffet, E. The Hospital
for Sick Children, Toronto, ON, Canada.
Background: Atypical teratoid/Rhabdoid tumors (ATRT) of the
brain are highly malignant central nervous system (CNS) tumors
which carry a grave prognosis. It comprises up to 15% of malignant
brain tumors. Current treatment recommendations include maxi-
mal surgical resection followed by chemotherapy, with or without
radiation. Despite intensive therapy, the prognosis is poor and the
reported median survival range between 8–17 months; children
younger than 3-yrs of age carry an even worse prognosis. High
dose chemotherapy (HDC) with autologous hematopoietic stem
cell transplant (AHSCT) has been proposed in order to improve
survival. Patients and Methods: A cohort of consecutive children
with ATRT at the Hospital for Sick Children, Toronto, (2000 to
2006). Treatment recommendation during that period was maxi-
mum surgical resection, intensive chemotherapy followed by 3
courses of sequential HDC (with thiotepa and carboplatin) with
AHSCT. Radiation treatment and adjuvant therapy were discussed
case by case. Results: Eight children with ATRT were evaluated in
the study period; 3 patients younger than 1 year with disseminated
disease were not treated. Five patients were treated (demographics,
tumor characteristics, treatment and outcome summarized in the ta-
ble). A total of 15 courses ofHDCandAHSCTwere performed in 5
patients. There was no treatment related mortality (TRM) follow-
ing HDC; 3 children had febrile neutropenia. Blood cultures in
all episodes were negative. One patient required admission to inten-
sive care unit for a short period. All patients developed mucositis
and were treated with morphine. Engraftment occurred at a mean
